Top

Published in:

22-02-2022 | Adenovirus | Review

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review

Authors: Swarnali Das, Suvrendu Sankar Kar, Sovan Samanta, Jhimli Banerjee, Biplab Giri, Sandeep Kumar Dash

Published in: Immunologic Research | Issue 3/2022

Abstract

SARS-CoV-2 is an RNA virus that was identified for the first time in December 2019 in Wuhan, China. The World Health Organization (WHO) labeled the novel coronavirus (COVID-19) outbreak a worldwide pandemic on March 11, 2020, due to its widespread infectivity pattern. Because of the catastrophic COVID-19 outbreak, the development of safe and efficient vaccinations has become a key priority in every health sector throughout the globe. On the 13th of January 2021, the vaccination campaign against SARS-CoV-2 was launched in India and started the administration of two types of vaccines known as Covaxin and Covishield. Covishield is an adenovirus vector-based vaccine, and Covaxin was developed by a traditional method of vaccine formulation, which is composed of adjuvanted inactivated viral particles. Each vaccine’s utility or efficiency is determined by its formulation, adjuvants, and mode of action. The efficacy of the vaccination depends on numeral properties like generation antibodies, memory cells, and cell-mediated immunity. According to the third-phase experiment, Covishield showed effectiveness of nearly 90%, whereas Covaxin has an effectiveness of about 80%. Both vaccination formulations in India have so far demonstrated satisfactory efficacy against numerous mutant variants of SARS-CoV-2. The efficacy of Covishield may be diminished if the structure of spike (S) protein changes dramatically in the future. In this situation, Covaxin might be still effective for such variants owing to its ability to produce multiple antibodies against various epitopes. This study reviews the comparative immunogenic and therapeutic efficacy of Covaxin and Covishield and also discussed the probable vaccination challenges in upcoming days.

Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163–88. https://doi.org/10.1016/bs.aivir.2018.01.001.CrossRefPubMedPubMedCentral

Hafeez A, Ahmad S, Siddqui SA, Ahmad M, Mishra S. A review of COVID-19 (coronavirus disease-2019) diagnosis, treatments and prevention. EJMO. 2020;4(2):116–25. https://doi.org/10.14744/ejmo.2020.90853.CrossRef

Sohrabi C, Alsafi Z, O’neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R. World Health Organization declares global emergency: a review of the novel coronavirus (COVID-19). Int J Surg. 2019;2020(76):71–6. https://doi.org/10.1016/j.ijsu.2020.02.034.CrossRef

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–93. https://doi.org/10.1001/jama.2020.12839.CrossRefPubMed

Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157. https://doi.org/10.23750/abm.v91i1.9397.CrossRefPubMedPubMedCentral

World Health Organization. WHO coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (Accessed 19^th December, 2020).

Jordan SC. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. Clin Exp Immunol. 2021;204(3):310–20. https://doi.org/10.1111/cei.13582.CrossRefPubMedPubMedCentral

Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Immune response in COVID-19: a review. J Infect Public Health. 2020;13(11):1619–29. https://doi.org/10.1016/j.jiph.2020.07.001.CrossRefPubMedPubMedCentral

Subbarao K, Mahanty S. Respiratory virus infections: understanding COVID-19. Immunity. 2020;52(6):905–9. https://doi.org/10.1016/j.immuni.2020.05.004.CrossRefPubMedPubMedCentral

10.

Chen PL, Lee NY, Cia CT, Ko WC, Hsueh PR. A review of treatment of coronavirus disease 2019 (COVID-19): therapeutic repurposing and unmet clinical needs. Front Pharmacol. 2020;11https://doi.org/10.3389/fphar.2020.584956

11.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–36. https://doi.org/10.1001/jama.2020.6019.CrossRefPubMed

12.

Kumar VM, Pandi-Perumal SR, Trakht I, Thyagarajan SP. Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. NPJ Vaccines. 2021;6(1):1–7. https://doi.org/10.1038/s41541-021-00327-2.CrossRef

13.

Thiagarajan K. COVID-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust. BMJ. 2021;372:n196. https://doi.org/10.1136/bmj.n196.CrossRefPubMed

14.

Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020;396(10255):887–97. https://doi.org/10.1016/S0140-6736(20)31866-3.CrossRef

15.

Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69(4):635–64. https://doi.org/10.1128/MMBR.69.4.635-664.2005.CrossRefPubMedPubMedCentral

16.

Binns C, Low WY, Kyung LM. The COVID-19 pandemic: public health and epidemiology. Asia Pac J Public Health. 2020;32(4):140–4. https://doi.org/10.1177/1010539520929223.CrossRefPubMedPubMedCentral

17.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. https://doi.org/10.1056/NEJMoa2001017.CrossRefPubMedPubMedCentral

18.

Astuti I. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes MetabSyndr: Clin Res Rev. 2020;14(4):407–12. https://doi.org/10.1016/j.dsx.2020.04.020.CrossRef

19.

Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect. 2021;54(2):159–63. https://doi.org/10.1016/j.jmii.2020.03.022.CrossRefPubMed

20.

Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3–20. https://doi.org/10.1038/s41580-021-00418-x.CrossRefPubMed

21.

Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, Droese B, Klaus JP, Makino S, Sawicki SG, Siddell SG. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol. 2011;174(1):11–22. https://doi.org/10.1016/j.jsb.2010.11.021.CrossRefPubMed

22.

DeDiego ML, Álvarez E, Almazán F, Rejas MT, Lamirande E, Roberts A, Shieh WJ, Zaki SR, Subbarao K, Enjuanes L. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol. 2007;81(4):1701–13. https://doi.org/10.1128/JVI.01467-06.CrossRefPubMed

23.

Mei J, Zhao D, Strotmann A. Intellectual structure of coronavirus research: a perspective from an author cocitation analysis. Front Res Metr. 2020;5:13. https://doi.org/10.3389/frma.2020.595370.CrossRef

24.

Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117(21):11727–34. https://doi.org/10.1073/pnas.2003138117.CrossRefPubMedPubMedCentral

25.

Dos Santos WG. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomed Pharmacother. 2021;12:111272. https://doi.org/10.1016/j.biopha.2021.111272.CrossRef

26.

Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020;324(13):1279–81. https://doi.org/10.1001/jama.2020.16656.CrossRefPubMed

27.

Yaqinuddin A, Kashir J. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents. Med Hypotheses. 2020;140:109777. https://doi.org/10.1016/j.mehy.2020.109777.CrossRefPubMedPubMedCentral

28.

Pan Y, Zhang D, Yang P, Poon LL, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020;20(4):411–2. https://doi.org/10.1016/S1473-3099(20)30113-4.CrossRefPubMedPubMedCentral

29.

Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Int Med. 2020;180(7):934–43. https://doi.org/10.1001/jamainternmed.2020.0994.CrossRef

30.

Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9:2379. https://doi.org/10.3389/fimmu.2018.02379.CrossRefPubMedPubMedCentral

31.

Manik M, Singh RK. Role of toll‐like receptors in modulation of cytokine storm signaling in SARS‐CoV‐2‐induced COVID‐19. J Med Virol. 2021;21:1–9. https://doi.org/10.1002/jmv.27405.CrossRef

32.

Livia O, Caraglia M, Facchini G, Margherita V, De Placido S, Buonerba C. Toll-like receptors and COVID-19: a two-faced story with an exciting ending. Future Sci OA. 2020;6(8):FSO605. https://doi.org/10.2144/fsoa-2020-0091.CrossRef

33.

Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801. https://doi.org/10.1016/j.cell.2006.02.015.CrossRefPubMed

34.

Taefehshokr N, Taefehshokr S, Hemmat N, Heit B. COVID-19: perspectives on innate immune evasion. Frontiers in immunology. 2020;11.

35.

Manjili RH, Zarei M, Habibi M, Manjili MH. COVID-19 as an acute inflammatory disease. J Immunol. 2020;205(1):12–9.CrossRefPubMed

36.

Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84. https://doi.org/10.1038/ni.1863.CrossRefPubMed

37.

Banerjee J, Dey S, Ali KM, Giri B, Dash SK. Advancements in adjuvanticity of bioactive inorganic and organic compounds. Endocr Metab Immune Disord. 2021;21(10):1721–43. https://doi.org/10.2174/1871530321666210225104819.CrossRef

38.

de Marcken M, Dhaliwal K, Danielsen AC, Gautron AS, Dominguez-Villar M. TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Sci Signal. 2019; 29;12(605). https://doi.org/10.1126/scisignal.aaw1347

39.

Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, Debnath O, Thürmann L, Kurth F, Völker MT, Kazmierski J. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38(8):970–9. https://doi.org/10.1038/s41587-020-0602-4.CrossRefPubMed

40.

Kell AM, Gale M Jr. RIG-I in RNA virus recognition. Virology. 2015;479:110–21. https://doi.org/10.1016/j.virol.2015.02.017.CrossRefPubMed

41.

Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, Goldeck M, Schuberth C, Van der Veen AG, Fujimura T, Rehwinkel J, Iskarpatyoti JA. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates. Nature. 2014;514(7522):372–5. https://doi.org/10.1038/nature13590.CrossRefPubMedPubMedCentral

42.

Kim YK, Shin JS, Nahm MH. NOD-like receptors in infection, immunity, and diseases. Yonsei Med J. 2016;57(1):5–14. https://doi.org/10.3349/ymj.2016.57.1.5.CrossRefPubMed

43.

Kozlov EM, Ivanova E, Grechko AV, Wu WK, Starodubova AV, Orekhov AN. Involvement of oxidative stress and the innate immune system in SARS-CoV-2 infection. Diseases. 2021;9(1):17. https://doi.org/10.3390/diseases9010017.CrossRefPubMedPubMedCentral

44.

Charles TP, Shellito JE. Human immunodeficiency virus infection and host defense in the lungs. Semin Respir Crit Care Med. 2016;37(02):147–56. https://doi.org/10.1055/s-0036-1572553.CrossRefPubMedPubMedCentral

45.

Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol. 2007;7(7):543–55. https://doi.org/10.1038/nri2103.CrossRefPubMed

46.

Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. From innate immunity to immunological memory. 2006:17–58. https://doi.org/10.1007/3-540-32636-7_2

47.

Cervantes-Barragán L, Kalinke U, Züst R, König M, Reizis B, López-Macías C, Thiel V, Ludewig B. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol. 2009;182(2):1099–106. https://doi.org/10.4049/jimmunol.182.2.1099.CrossRefPubMed

48.

Glasner A, Zurunic A, Meningher T, LenacRovis T, Tsukerman P, Bar-On Y, Yamin R, Meyers AF, Mandeboim M, Jonjic S, Mandelboim O. Elucidating the mechanisms of influenza virus recognition by Ncr1. PLoS ONE. 2012;7(5):e36837. https://doi.org/10.1371/journal.pone.0036837.CrossRefPubMedPubMedCentral

49.

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–5. https://doi.org/10.1038/s41423-020-0402-2.CrossRefPubMedPubMedCentral

50.

Guihot A, Litvinova E, Autran B, Debré P, Vieillard V. Cell-mediated immune responses to COVID-19 infection. Front Immunol. 2020;11:1662. https://doi.org/10.3389/fimmu.2020.01662.CrossRefPubMedPubMedCentral

51.

Braud VM, Allan DS, O’Callaghan CA, Söderström K, D’Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL. HLA-E binds to natural killer cell receptors CD94/NKG2A. B and C Nature. 1998;391(6669):795–9. https://doi.org/10.1038/35869.CrossRef

52.

Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types. Front Physiol. 2018;9:113. https://doi.org/10.3389/fphys.2018.00113.CrossRefPubMedPubMedCentral

53.

Zuo Y, Zuo M, Yalavarthi S, Gockman K, Madison JA, Shi H, Woodard W, Lezak SP, Lugogo NL, Knight JS, Kanthi Y. Neutrophil extracellular traps and thrombosis in COVID-19. J Thromb Thrombolysis. 2021;51(2):446–53. https://doi.org/10.1007/s11239-020-02324-z.CrossRefPubMed

54.

Ali YM, Ferrari M, Lynch NJ, Yaseen S, Dudler T, Gragerov S, Demopulos G, Heeney JL, Schwaeble WJ. Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front Immunol. 2021;12:2645. https://doi.org/10.3389/fimmu.2021.714511.CrossRef

55.

Jarlhelt I, Nielsen SK, Jahn CX, Hansen CB, Pérez-Alós L, Rosbjerg A, Bayarri-Olmos R, Skjoedt MO, Garred P. SARS-CoV-2 antibodies mediate complement and cellular driven inflammation. Front. Immunol. 2021;12. https://doi.org/10.3389/fimmu.2021.767981

56.

Chen G, Wu DI, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020;1 130(5):2620–9. https://doi.org/10.1172/JCI137244.CrossRefPubMed

57.

Jansen JM, Gerlach T, Elbahesh H, Rimmelzwaan GF, Saletti G. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. J Clin Virol. 2019;119:44–52. https://doi.org/10.1016/j.jcv.2019.08.009.CrossRefPubMed

58.

Jenkins MK, Khoruts A, Ingulli E, Mueller DL, McSorley SJ, Reinhardt RL, Itano A, Pape KA. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol. 2001;19(1):23–45. https://doi.org/10.1146/annurev.immunol.19.1.23.CrossRefPubMed

59.

Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012;4(3):a006049. https://doi.org/10.1101/cshperspect.a006049.CrossRefPubMedPubMedCentral

60.

Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36–49. https://doi.org/10.1038/nri3581.CrossRefPubMedPubMedCentral

61.

Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371(6529). https://doi.org/10.1126/science.abf4063

62.

Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, O’Mahony L, Gao Y, Nadeau K, Akdis CA. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564–81. https://doi.org/10.1111/all.14364.CrossRefPubMed

63.

Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;71(15):778–85. https://doi.org/10.1093/cid/ciaa310.CrossRefPubMed

64.

Yu HQ, Sun BQ, Fang ZF, Zhao JC, Liu XY, Li YM, Sun XZ, Liang HF, Zhong B, Huang ZF, Zheng PY. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020; 56(2). https://doi.org/10.1183/13993003.01526-2020

65.

Fourati S, Hue S, Pawlotsky JM, Mekontso-Dessap A, de Prost N. SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients. Intensive Care Med. 2020;46(9):1781–3. https://doi.org/10.1007/s00134-020-06157-5.CrossRefPubMedPubMedCentral

66.

Stephens DS, McElrath MJ. COVID-19 and the path to immunity. Jama. 2020;6 324(13):1279–8. https://doi.org/10.1001/jama.2020.16656.CrossRef

67.

Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46–61. https://doi.org/10.1038/nri.2017.106.CrossRefPubMed

68.

Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol. 2020;7(11):1949. https://doi.org/10.3389/fimmu.2020.01949.CrossRef

69.

Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, Marrama D. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–501. https://doi.org/10.1016/j.cell.2020.05.015.CrossRefPubMedPubMedCentral

70.

Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355–62. https://doi.org/10.1038/s41577-020-0331-4.CrossRefPubMedPubMedCentral

71.

Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–4. https://doi.org/10.1038/s41586-020-2179-y.CrossRefPubMedPubMedCentral

72.

Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;12:1–8. https://doi.org/10.1007/s11684-020-0754-0.CrossRef

73.

Zhang H, Li HB, Lyu JR, Lei XM, Li W, Wu G, Lyu J, Dai ZM. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int J Infect Dis. 2020;96:19–24. https://doi.org/10.1016/j.ijid.2020.04.027.CrossRefPubMedPubMedCentral

74.

Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100–15. https://doi.org/10.1016/j.it.2020.10.004.CrossRefPubMedPubMedCentral

75.

Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7(6):439–50. https://doi.org/10.1038/nrmicro2147.CrossRefPubMedPubMedCentral

76.

Snijder EJ, Van Der Meer Y, Zevenhoven-Dobbe J, Onderwater JJ, Van Der Meulen J, Koerten HK, Mommaas AM. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J Virol. 2006;80(12):5927–40. https://doi.org/10.1128/JVI.02501-05.CrossRefPubMedPubMedCentral

77.

Wu HY, Brian DA. Subgenomic messenger RNA amplification in coronaviruses. Proc Natl Acad Sci U S A. 2010;107(27):12257–62. https://doi.org/10.1073/pnas.1000378107.CrossRefPubMedPubMedCentral

78.

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74. https://doi.org/10.1038/s41577-020-0311-8.CrossRefPubMed

79.

Martin TR, Wurfel MM, Zanoni I, Ulevitch R. Targeting innate immunity by blocking CD14: novel approach to control inflammation and organ dysfunction in COVID-19 illness. EBio Med. 2020;57:102836. https://doi.org/10.1016/j.ebiom.2020.102836.CrossRef

80.

Amor S, Fernández Blanco L, Baker D. Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage. Clin Exp Immunol. 2020;202(2):193–209. https://doi.org/10.1111/cei.13523.CrossRefPubMedPubMedCentral

81.

Min YQ, Huang M, Sun X, Deng F, Wang H, Ning YJ. Immune evasion of SARS-CoV-2 from interferon antiviral system. Comput Struct Biotechnol J. 2021;19:4217–25. https://doi.org/10.1016/j.csbj.2021.07.023.CrossRefPubMedPubMedCentral

82.

Yoshikawa T, Hill TE, Yoshikawa N, Popov VL, Galindo CL, Garner HR, Peters CJ, Tseng CT. Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection. PLoS ONE. 2010;5(1):e8729. https://doi.org/10.1371/journal.pone.0008729.CrossRefPubMedPubMedCentral

83.

Shemesh M, Aktepe TE, Deerain JM, McAuley JL, Audsley MD, David CT, Purcell DF, Urin V, Hartmann R, Moseley GW, Mackenzie JM. SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. PLoSPathog. 2021;17(8):e1009800. https://doi.org/10.1371/journal.ppat.1009800.CrossRef

84.

Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, Wang C, Wang Y, Li L, Ren L, Guo F. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11(1):1–2. https://doi.org/10.1038/s41467-020-17665-9.CrossRef

85.

Jefferies CA. Regulating IRFs in IFN driven disease. Front Immunol. 2019;10:325. https://doi.org/10.3389/fimmu.2019.00325.CrossRefPubMedPubMedCentral

86.

Siu KL, Chan CP, Kok KH, Woo PC, Jin DY. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cell Mol Immunol. 2014;11(2):141–9. https://doi.org/10.1038/cmi.2013.61.CrossRefPubMedPubMedCentral

87.

Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75. https://doi.org/10.1016/j.cytogfr.2020.06.001.CrossRefPubMedPubMedCentral

88.

Lucas C, Wong P, Klein J, Castro TB, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, Takahashi T. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463–9. https://doi.org/10.1038/s41586-020-2588-y.CrossRefPubMedPubMedCentral

89.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.CrossRefPubMed

90.

Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;19 52(5):731–3. https://doi.org/10.1016/j.immuni.2020.04.003.CrossRef

91.

Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Sun R, Tian Z, Xu X, Wei H. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. BioRxiv.2020 Jan 1. https://doi.org/10.1093/nsr/nwaa041

92.

Yeap WH, Wong KL, Shimasaki N, Teo EC, Quek JK, Yong HX, Diong CP, Bertoletti A, Linn YC, Wong SC. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. Sci Rep. 2016;6(1):1–22. https://doi.org/10.1038/srep34310.CrossRef

93.

Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–4. https://doi.org/10.1126/science.abb8925.CrossRefPubMed

94.

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–32. https://doi.org/10.1002/jmv.25685.CrossRefPubMedPubMedCentral

95.

Rayamajhi M, Zhang Y, Miao EA. Detection of pyroptosis by measuring released lactate dehydrogenase activity. Methods Mol Biol. 2013;1040:85–90. https://doi.org/10.1007/978-1-62703-523-1_7.CrossRefPubMedPubMedCentral

96.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–2. https://doi.org/10.1016/S2213-2600(20)30076-X.CrossRefPubMedPubMedCentral

97.

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J ThrombHaemost. 2020;18(4):844–7. https://doi.org/10.1111/jth.14768.CrossRef

98.

Java A, Apicelli AJ, Liszewski MK, Coler-Reilly A, Atkinson JP, Kim AH, Kulkarni HS. The complement system in COVID-19: friend and foe?. JCI insight. 2020; 6: 5(15). https://doi.org/10.1172/jci.insight.140711

99.

Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Panigada M, Aliberti S, Blasi F, Tedesco F, Peyvandi F. Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol. 2020;146(1):215. https://doi.org/10.1016/j.jaci.2020.05.006.CrossRefPubMedPubMedCentral

100.

Jodele S, Köhl J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol. 2021;178(14):2832–48. https://doi.org/10.1111/bph.15187.CrossRefPubMed

101.

Mastellos DC, da Silva BG, Fonseca BA, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol. 2020;220:108598. https://doi.org/10.1016/j.clim.2020.108598.CrossRefPubMedPubMedCentral

102.

Liao M, Liu Y, Yuan J, et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. Nat Med. 2020;26:842–4. https://doi.org/10.1101/2020.02.23.20026690.CrossRefPubMed

103.

Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stageby single-cell sequencing. Cell Discov. 2020;6(1):31. https://doi.org/10.1038/s41421-020-0168-9.CrossRefPubMedPubMedCentral

104.

Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992–1000. https://doi.org/10.1016/j.chom.2020.04.009.CrossRefPubMedPubMedCentral

105.

Diao B, Wang C, Tan Y. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020; 11(827). https://doi.org/10.3389/fimmu.2020.00827

106.

van Erp EA, van Kampen MR, van Kasteren PB, et al. Viral infection of human natural killer cells. Viruses. 2019;11(3):243. https://doi.org/10.3390/v11030243.CrossRefPubMedCentral

107.

Yao C, Bora SA, Parimon T, Zaman T, Friedman OA, Palatinus JA, Surapaneni NS, Matusov YP, Chiang GC, Kassar AG, Patel N. Cell-type-specific immune dysregulation in severely ill COVID-19 patients. Cell Rep. 2021;34(1):108590. https://doi.org/10.1101/2020.07.23.20161182.CrossRefPubMed

108.

Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol. 2020;11:1949. https://doi.org/10.3389/fimmu.2020.01949.CrossRefPubMedPubMedCentral

109.

Lau YL, Peiris J, Law HKW, et al. Role of dendritic cells in SARS coronavirus infection. Hong Kong Med J. 2012;18:28–30.PubMed

110.

Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–27. https://doi.org/10.1038/s41586-020-2798-3.CrossRefPubMed

111.

World Health Organization. DRAFT landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines Accessed 4 March 2020.

112.

Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:2413. https://doi.org/10.3389/fimmu.2020.585354.CrossRef

113.

Dash P, Mohapatra S, Ghosh S, Nayak B. A scoping insight on potential prophylactics, vaccines and therapeutic weaponry for the ongoing novel coronavirus (COVID-19) pandemic-a comprehensive review. Front Pharmacol. 2021;11:2471. https://doi.org/10.3389/fphar.2020.590154.CrossRef

114.

Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615–32. https://doi.org/10.1038/s41577-020-00434-6.CrossRefPubMedPubMedCentral

115.

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 2020;8 324(10):951–60. https://doi.org/10.1001/jama.2020.15543.CrossRefPubMed

116.

Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol. 2018;40:83–94. https://doi.org/10.1016/j.smim.2018.10.010.CrossRefPubMed

117.

Belete TM. Review on up-to-date status of candidate vaccines for COVID-19 disease. Infect Drug Resist. 2021;14:151. https://doi.org/10.2147/IDR.S288877.CrossRefPubMedPubMedCentral

118.

Khuroo MS, Khuroo M, Khuroo MS, Sofi AA, Khuroo NS. COVID-19 vaccines: a race against time in the middle of death and devastation. J Clin Exp Hepatol. 2020;10:610–21. https://doi.org/10.1016/j.jceh.2020.06.003.CrossRefPubMedPubMedCentral

119.

Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;288:198114. https://doi.org/10.1016/j.virusres.2020.198114.CrossRefPubMedPubMedCentral

120.

Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M, Yang M. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722–33. https://doi.org/10.1016/j.cell.2020.06.035.CrossRefPubMedPubMedCentral

121.

Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm. 2008;364:272–80. https://doi.org/10.1016/j.ijpharm.2008.04.036.CrossRefPubMed

122.

Piyush R, Rajarshi K, Chatterjee A, Khan R, Ray S. Nucleic acid-based therapy for coronavirus disease 2019. Heliyon. 2020;19:e05007. https://doi.org/10.1016/j.heliyon.2020.e05007.CrossRef

123.

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;14. https://doi.org/10.1056/NEJMoa2022483

124.

Wang F, Kream RM, Stefano GB. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci Monit. 2020;26:e924700-1. https://doi.org/10.12659/MSM.924700.CrossRefPubMedPubMedCentral

125.

Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. Medrxiv. 2020 https://doi.org/10.1056/NEJMoa2027906

126.

ClinicalTrials.gov. Identifier: NCT04336410. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04336410. Accessed May2, 2020

127.

Saini P. COVID-19 pandemic: potential phase III vaccines in development. T Appl Biol Chem J. 2020;1(1):21-33. https://doi.org/10.52679/tabcj.2020.0004

128.

Thiagarajan K. What do we know about India’s Covaxin vaccine?. BMJ: British Medical Journal (Online). 2021 Apr 20;373. https://doi.org/10.1136/bmj.n997

129.

Zhang N, Li C, Hu Y, Li K, Liang J, Wang L, Du L, Jiang S. Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes Infect. 2020;22(6–7):231–5. https://doi.org/10.1016/j.micinf.2020.05.001.CrossRefPubMedPubMedCentral

130.

Gharate JS, Daitkar SA, Aher KA. Approved COVID 19 vaccines: a review. World J Pharm Res. 2021;10(10):523–42.

131.

Vogel FR. Improving vaccine performance with adjuvants. Clin Infect Dis. 2000; 30(Supplement_3):S266–70. https://doi.org/10.1086/313883

132.

Liang Z, Zhu H, Wang X, Jing B, Li Z, Xia X, Sun H, Yang Y, Zhang W, Shi L, Zeng H. Adjuvants for coronavirus vaccines Front Immunol. 2020;11:2896. https://doi.org/10.3389/fimmu.2020.589833.CrossRef

133.

Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, Sharma A. Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: the final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine. 2021;39(44):6492–509. https://doi.org/10.1016/j.vaccine.2021.09.055.CrossRefPubMedPubMedCentral

134.

Malabadi RB, Meti NT, Chalannavar RK. Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (Covid-19). Int J Res Sci Inno. 2021;8(2):191–8.

135.

Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–91. https://doi.org/10.1016/S0140-6736(21)00432-3.

136.

Thiagarajan K. What do we know about India’s Covaxin vaccine. bmj. 2021;373:n997. https://doi.org/10.1136/bmj.n997.CrossRefPubMed

137.

Misra SK, Pathak K, Pathak D, Yadav R. Current updates on COVID-19 vaccines. Asian J Pharm Clin Res. 2021;7:17–23. https://doi.org/10.22159/ajpcr.2021v14i5.41061.CrossRef

138.

World Health Organization. Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: interim guidance, 3 November 2021.

139.

Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, Das D, Raju D, Praturi U, Sapkal G, Yadav P, Reddy P, Verma S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Bhate A, Rai S, Panda S, Abraham P, Gupta N, Ella K, Bhargava B, Vadrevu KM. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21(7):950–61. https://doi.org/10.1016/S1473-3099(21)00070-0.CrossRefPubMedPubMedCentral

140.

Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, Panda S, Gupta N, Reddy P, Verma S, Kumar Rai S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Rao V, Guleria R, Ella K, Bhargava B. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a doubleblind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21(5):637–46. https://doi.org/10.1016/S1473-3099(20)30942-7.CrossRefPubMedPubMedCentral

141.

Ganneru B, Jogdand H, Daram VK, Das D, Molugu NR, Prasad SD, Kannappa SV, Ella KM, Ravikrishnan R, Awasthi A, Jose J. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. Iscience. 2021;24(4):102298. https://doi.org/10.1016/j.isci.2021.102298.CrossRefPubMedPubMedCentral

142.

García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441. https://doi.org/10.3389/fimmu.2020.01441.CrossRefPubMedPubMedCentral

143.

Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu rev immunol. 2003;21:685711. https://doi.org/10.1146/annurev.immunol.21.120601.141040.CrossRef

144.

Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology. 2008;123(3):326–38. https://doi.org/10.1111/j.1365-2567.2007.02719.x.CrossRefPubMedPubMedCentral

145.

Abbas AK, Burstein HJ, Bogen SA. Determinants of helper T cell-dependent antibody production. Semin Immunol. 1993;5(6):441–7. https://doi.org/10.1006/smim.1993.1050.CrossRefPubMed

146.

Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses: naive to memory and everything in between. Adv Physiol Educ. 2013;37(4):273–83. https://doi.org/10.1152/advan.00066.2013.CrossRefPubMedPubMedCentral

147.

Dörner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity. 2007;21 27(3):384–92. https://doi.org/10.1016/j.immuni.2007.09.002.CrossRef

148.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–78. https://doi.org/10.1016/S0140-6736(20)31604-4.CrossRefPubMedPubMedCentral

149.

Flanagan KL, Best E, Crawford NW, Giles M, Koirala A, Macartney K, Russell F, Teh BW, Wen SC. Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines. Front Immunol. 2020;11:2410. https://doi.org/10.3389/fimmu.2020.579250.CrossRef

150.

Goyal K, Goel H, Baranwal P, Tewary A, Dixit A, Pandey AK, Benjamin M, Tanwar P, Dey A, Khan F, Pandey P. Immunological mechanisms of vaccine-induced protection against SARS-CoV-2 in humans. Immuno. 2021;1(4):442–56. https://doi.org/10.3390/immuno1040032.CrossRef

151.

Kovesdi I, Hedley SJ. Adenoviral producer cells. Vaccine. 2010;2:1681–703. https://doi.org/10.3390/v2081681.CrossRef

152.

Doerfler W. Adenoviral vector DNA-and SARS-CoV-2 mRNA-based COVID-19 vaccines: possible integration into the human genome-are adenoviral genes expressed in vector-based vaccines? Virus Res. 2021;302:198466. https://doi.org/10.1016/j.virusres.2021.198466.CrossRefPubMedPubMedCentral

153.

Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):1–4. https://doi.org/10.1038/s41392-020-00352-y.CrossRef

154.

Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care. 2021;25(1):1–8. https://doi.org/10.1186/s13054-021-03662-x.CrossRef

155.

Garcia-Beltran WF, Lam EC, Denis KS, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC, Sigal A. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–83. https://doi.org/10.1016/j.cell.2021.03.013.CrossRefPubMedPubMedCentral

156.

Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, Rakshit P, Singh S, Abraham P, Panda S, Team NI. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Microorganisms. 2021;9(7):1542. https://doi.org/10.3390/microorganisms9071542.CrossRefPubMedPubMedCentral

157.

Joshi SR, Pandit R, Parikh P, Gulia A. Containing COVID-19 second surge in India. Indian J Med Sci. 2021;73:1. https://doi.org/10.25259/IJMS_157_2021.CrossRefPubMedCentral

158.

Sahoo JP, Mishra AP, Samal KC. Triple mutant Bengal strain (B. 1.618) of coronavirus and the worst COVID outbreak in India. Biol Res Tod. 2021;3(4):261–5.

159.

Aleem A, AB AS, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19).

160.

Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, Lorson CL, Byrareddy SN, Singh K. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. J Autoimmun. 2021;124:102715. https://doi.org/10.1016/j.jaut.2021.102715.CrossRefPubMedPubMedCentral

161.

Mahase E. COVID-19: do vaccines work against omicron—and other questions answered. BMJ 2021; 375 https://doi.org/10.1136/bmj.n3062

162.

Zuckerman NS, Fleishon S, Bucris E, Bar-Ilan D, Linial M, Bar-Or I, Indenbaum V, Weil M, Lustig Y, Mendelson E, Mandelboim M. A unique SARS-CoV-2 spike protein P681H variant detected in Israel. Vaccines. 2021;9(6):616. https://doi.org/10.3390/vaccines9060616.CrossRefPubMedPubMedCentral

163.

Duong D. Alpha, Beta, Delta, Gamma: what’s important to know about SARS-CoV-2 variants of concern? Can Med Assoc J. 2021;193(27):E1059–60. https://doi.org/10.1503/cmaj.1095949.CrossRef

164.

Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant. N Engl J Med. 2021;384(20):1885–98. https://doi.org/10.1056/NEJMoa2102214.CrossRefPubMed

165.

Faria NR, Claro IM, Candido D, Franco LM, Andrade PS, Coletti TM, Silva CA, Sales FC, Manuli ER, Aguiar RS, Gaburo N. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological. 2021;12(372):815–21. https://doi.org/10.1101/2021.02.26.21252554.CrossRef

166.

American society of microbiology. How-Dangerous-is-the-Delta-Variant-B-1–617–2. https://asm.org/Articles/2021/July. (Accessed in 15^th December, 2021).

167.

Bruxvoort K, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, Tian Y, Florea A, Aragones M, Tubert JE, Takhar HS. Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants. medRxiv. 2021;375:e068848. https://doi.org/10.1136/bmj-2021-068848.CrossRef

168.

Wadman M. California coronavirus strain may be more infectious—and lethal. Science. 2021 (Accessed in 15^th December, 2021).

169.

Zhang W, Davis BD, Chen SS, Martinez JM, Plummer JT, Vail E. Emergence of a novel SARS-CoV-2 variant in Southern California. JAMA Netw Open. 2021;325(13):1324–6. https://doi.org/10.1001/jama.2021.1612.CrossRef

170.

World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ WHO. (Accessed in 15^th December, 2021).

171.

Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Tanaka YL, Liu Y, Shirakawa K, Kazuma Y, Nomura R, Horisawa Y. SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. BioRxiv.2021 Jan 1. https://doi.org/10.1101/2021.07.28.454085

172.

Outbreak. Info. Lineage. Mutation Tracker, Mu Variant Report. https://outbreak.info/situation-reports/Mu (Accessed in 15^th December, 2021).

173.

Fratev F. The R346K mutation in the Mu variant of SARS-CoV-2 alter the interactions with monoclonal antibodies from class 2: a free energy of perturbation study. BioRxiv. 2021 https://doi.org/10.1101/2021.10.12.463781

174.

UK Health Security Agency. SARS-CoV WH. Variants of concern and variants of interest, updated 31 May 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1042367/technical_briefing-31-10-december-2021.pdf. (Accessed in 19^th December, 2021).

175.

Pfize. Pfizer and BioNTech provide update on Omicron variant. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant (Accessed in 19th December, 2021).

176.

Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, Vadrevu KM, Abraham P, Panda S, Bhargava B. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B. 1.1. 7 variant of SARS-CoV-2. J Trav Med. 2021;28:51. https://doi.org/10.1093/jtm/taab051.CrossRef

177.

Karim SS. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. Lancet. 2021;397:1263–4. https://doi.org/10.1016/S0140-6736(21)00468-2.CrossRefPubMedPubMedCentral

178.

Bhasker B. COVID 19 vaccination: latest guidelines on blood donor deferral in India. Transfus Clin Biol. 2021;28(3):299. https://doi.org/10.1016/j.tracli.2021.05.005.CrossRefPubMedPubMedCentral

179.

Kashte S, Gulbake A, El-Amin SF III, Gupta A. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum cell. 2021;7:1–23. https://doi.org/10.1007/s13577-021-00512-4.CrossRef

180.

Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503. https://doi.org/10.1016/j.immuni.2010.10.002.CrossRefPubMedPubMedCentral

181.

Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;13:198114. https://doi.org/10.1016/j.virusres.2020.198114.CrossRef

182.

Jayadevan R, Shenoy RS, Anithadevi TS. Survey of symptoms following COVID-19 vaccination in India.Medrxiv.2021 .https://doi.org/10.1101/2021.02.08.21251366

183.

COVAXIN Factsheet-V4. Restricted use in emergency situation of COVID-19. https://www.bharatbiotech.com/images/covaxin/covaxin-factsheet.pdf (Accessed 19th December, 2021).

184.

Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397:642–3. https://doi.org/10.1016/S0140-6736(21)00191-4.CrossRefPubMedPubMedCentral

185.

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81. https://doi.org/10.1016/S0140-6736(21)00234-8.CrossRefPubMedPubMedCentral

186.

Pagliusi S, Jarrett S, Hayman B, Kreysa U, Prasad SD, Reers M, Thai PH, Wu K, Zhang YT, Baek YO, Kumar A. Emerging manufacturers engagements in the COVID− 19 vaccine research, development and supply. Vaccine. 2020;38(34):5418–23. https://doi.org/10.1016/j.vaccine.2020.06.022.CrossRefPubMedPubMedCentral

187.

Sharun K, Dhama K. India’s role in COVID-19 vaccine diplomacy. J. Travel Med. 2021 https://doi.org/10.1093/jtm/taab064

188.

Chavda VP, Vora LK, Pandya AK, Patravale VB. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today. 2021;26(11):2619–36. https://doi.org/10.1016/j.drudis.2021.07.021.CrossRefPubMedPubMedCentral

Title: Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
Authors: Swarnali Das
Suvrendu Sankar Kar
Sovan Samanta
Jhimli Banerjee
Biplab Giri
Sandeep Kumar Dash
Publication date: 22-02-2022
Publisher: Springer US
Keywords: Adenovirus
Vaccination
SARS-CoV-2
COVID-19
Published in: Immunologic Research / Issue 3/2022
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-022-09265-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Identification of nafamostat mesylate as a selective stimulator of NK cell IFN-γ production via metabolism-related compound library screening

Peripheral neuropathies during the COVID-19 pandemic: is there a relation?

PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy

An overview of the biological and multifunctional roles of IL-38 in different infectious diseases and COVID-19

CircCBFB is a mediator of hepatocellular carcinoma cell autophagy and proliferation through miR-424-5p/ATG14 axis

H19 is involved in the regulation of inflammatory responses in acute gouty arthritis by targeting miR-2-3p